Early validation for in vivo Car-T
ESO-T01 delivers its first four multiple myeloma case reports.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Safety remains the key metric for Cogent
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
BeOne tries to repeat the inhibitor-degrader double
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
A solid tumour Car-T first?
Satri-cel is filed for gastric cancer approval in China.
